Alpha¹ by KaimenConfidential

Kaimen Rigor review

Multifaceted Strategies for Hypertension Control in Low-Income Patients.

Mills KT, Krousel-Wood M, Peacock EM, Chen J, Allouch F, Carreras AK, Geng S, Cyprian A, Davis G, Fuqua SR, Gilliam D, Greer A, Mitchell T, Gray-Winfrey W, Williams S, Wiltz GM, Winfrey KL, He H, Whelton PK, He J

DOI: 10.1056/NEJMoa2504068
Record issued: 2026-08-10
Engine: 7.29.0
Exported: 2026-09-21

Prepared by Alpha1. This document is confidential: it is intended for the recipient it was shared with and must not be redistributed. The live record at alpha1science.com/verify/bba2ecb8-2818-4a0f-93e9-69a96d102e19 is authoritative.

Kaimen Rigor review

Kaimen Rigor reviewed

2.5 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsOverstated claim−0.5★
ReportingData & code availability not met−0.5★
ReportingEthical approvals partially met−0.25★
ReportingStatistical analysis partially met−0.25★

Model-reported confidence: highReviewer agreement: moderateEngine: 7.29.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run on this paper: the pass that reads its reported means did not complete. No reported mean was checked for arithmetic impossibility.

Biggest issues

01Data and code not shared
highDisclosurereviewer-assessedFull detail
No data availability statement is present, and no code is shared. A clinical trial identifier is provided, but that does not constitute a data availability statement.
02Conclusion reaches beyond the evidence
mediumOverreachreviewer-assessedFull detail
This proven, multifaceted strategy is scalable to other primary care settings to improve hypertension control in underserved populations.
“This proven, multifaceted strategy is scalable to other primary care settings to improve hypertension control in underserved populations.”
DiscussionFind in source

Findings by category

101ArithmeticNumerical inconsistencies 202OverreachOverstated conclusions 03AuthenticityNone found 304DisclosureReporting gaps 05AvailabilityNone found 106CopyeditCopyediting

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This cluster-randomized trial is methodologically rigorous with a well-justified premise, strong design, and thorough reporting of patient characteristics and outcomes. However, it lacks a data availability statement, contains minor copyedit errors (missing minus signs in CI bounds), and overstates the scalability of the strategy. The statistics are consistent where verifiable, ethical approval is documented but regulatory compliance is not stated, and the primary p-values are reported as thresholds.

Three independent rigor evaluations were synthesized; all three agreed on the status of most dimensions. The key resources dimension was rated not applicable because the study is a behavioral/implementation trial with no investigational product. The statistics verification covered 9 tests, all consistent, but cannot verify threshold-only p-values.

Numerical inconsistencies

1 finding · worst low

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Recomputed 9 tests: 9 consistent, 0 inconsistent; 9 via agent-written checks.

Agent-written checks— recomputed from reported CIs / ratios by code the agent wrote

CONSISTENTreported p = .800 · recomputed p = .811Reviewer 1
Serious adverse event net difference p-value recomputed from 95% CI
“| Serious adverse event, % | 20.9 (15.5, 26.3) | 21.7 (18.1, 25.4) | −0.8 (−7.4, 5.7) | 0.80 |”
Find in source
Taken as given: the CI is two-sided at 95%; the net difference and CI are from the unadjusted model; a normal approximation is adequate for this large sample
Method: Two-sided p from a 95% CI via normal approximation: SE=(upper-lower)/3.92, Z=estimate/SE.
How we recomputed it: pCI(-0.8, -7.4, 5.7, 0)
CONSISTENTreported p = .700 · recomputed p = .692Reviewer 1
Injurious fall net difference p-value recomputed from 95% CI
“| Injurious fall, % | 7.7 (3.1, 12.2) | 6.6 (3.7, 9.5) | 1.1 (−4.4, 6.5) | 0.70 |”
Find in source
Taken as given: the CI is two-sided at 95%; the net difference and CI are from the unadjusted model
Method: Two-sided p from a 95% CI via normal approximation.
How we recomputed it: pCI(1.1, -4.4, 6.5, 0)
CONSISTENTreported p = .660 · recomputed p = .663Reviewer 1
Syncope net difference p-value recomputed from 95% CI
“| Syncope, % | 3.7 (0.0, 7.4) | 2.6 (0.1, 5.2) | 1.0 (−3.5, 5.5) | 0.66 |”
Find in source
Taken as given: the CI is two-sided at 95%; the net difference and CI are from the unadjusted model
Method: Two-sided p from a 95% CI via normal approximation.
How we recomputed it: pCI(1.0, -3.5, 5.5, 0)
CONSISTENTreported p = .760 · recomputed p = .763Reviewer 1
Kidney transplant/dialysis net difference p-value recomputed from 95% CI
“| Kidney transplant or dialysis, % ‡‡ | 0.9 (−0.1, 1.8) | 0.7 (−0.2, 1.6) | 0.2 (−1.1, 1.5) | 0.76 |”
Find in source
Taken as given: the CI is two-sided at 95%; the net difference and CI are from the unadjusted model
Method: Two-sided p from a 95% CI via normal approximation.
How we recomputed it: pCI(0.2, -1.1, 1.5, 0)
CONSISTENTreported p = .510 · recomputed p = .514Reviewer 1
Hypotension net difference p-value recomputed from 95% CI
“| Hypotension, % ‡‡ | 1.0 (0.0, 1.9) | 0.6 (−0.1, 1.3) | 0.4 (−0.8, 1.6) | 0.51 |”
Find in source
Taken as given: the CI is two-sided at 95%; the net difference and CI are from the unadjusted model
Method: Two-sided p from a 95% CI via normal approximation.
How we recomputed it: pCI(0.4, -0.8, 1.6, 0)
CONSISTENTreported p < .001 · recomputed p = <.001Reviewer 1
Primary systolic BP co-primary outcome p-value recomputed from 95% CI
“with a net difference of −6.4 mmHg (95% CI, −9.0 to −3.8; P<0.001)”
Find in source
Taken as given: the CI is two-sided at 95%; the net difference and CI are from the primary mixed-effects model
Method: Two-sided p from a 95% CI via normal approximation; result far below 0.001.
How we recomputed it: pCI(-6.4, -9.0, -3.8, 0)
CONSISTENTreported p < .001 · recomputed p = <.001Reviewer 1
Fidelity summary score primary implementation outcome p-value recomputed from 95% CI
“with a between-group difference of 0.7 (95% CI, 0.6 to 0.8; P<0.001)”
Find in source
Taken as given: the CI is two-sided at 95%; the net difference and CI are from the unadjusted mixed-effects model
Method: Two-sided p from a 95% CI via normal approximation; result far below 0.001.
How we recomputed it: pCI(0.7, 0.6, 0.8, 0)
CONSISTENTreported p < .001 · recomputed p = <.001Reviewer 2
Primary effectiveness outcome: net difference in systolic BP change from baseline to 18 months.
“with a net difference of −6.4 mmHg (95% CI, −9.0 to −3.8; P<0.001)”
Find in source
Taken as given: The estimate is the mean difference in change from baseline between groups.; The 95% CI is symmetric and based on a normal approximation.; The CI is two-sided at 95% confidence.
Method: Two-tailed p-value computed from the effect estimate and its 95% confidence interval using the pCI function (normal approximation).
How we recomputed it: pCI(-6.4, -9.0, -3.8, 0)
CONSISTENTreported p < .001 · recomputed p = <.001Reviewer 2
Primary implementation outcome: net difference in fidelity summary score.
“with a between-group difference of 0.7 (95% CI, 0.6 to 0.8; P<0.001)”
Find in source
Taken as given: The estimate is the mean difference in fidelity score between groups.; The 95% CI is symmetric and based on a normal approximation.; The CI is two-sided at 95% confidence.
Method: Two-tailed p-value computed from the effect estimate and its 95% confidence interval using the pCI function (normal approximation).
How we recomputed it: pCI(0.7, 0.6, 0.8, 0)

lowinternal contradiction
Reported percentages for annual family income <$25,000 are ~0.5 percentage points higher than the exact count/group-N ratio (468/642=72.9% vs reported 73.4%; 460/630=73.0% vs reported 73.5%), suggesting the percentages may be computed on a slightly smaller non-missing denominator.
“Annual family income <$25,000 — no. (%) | 468 (73.4) | 460 (73.5)”
Table 1Find in source
lowinternal contradiction
Results text omits the minus signs on CI bounds for the primary and diastolic BP net differences, which contradicts Table 2; this is a transcription/copyedit error rather than a numerical inconsistency.
“net difference of −6.4 mmHg (95% CI, 9.0 to 3.8; P< 0.001)”
ResultsFind in source

Overstated conclusions

2 findings · worst medium

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Conclusions overstated beyond the evidenceAssessed
Conclusions only partially backed by the presented evidenceAssessed

6 major claims checked against the paper's own evidence: 1 not fully backed by the presented evidence (unsupported or overstated).

overstatedReviewers 1, 2, 3
This proven, multifaceted strategy is scalable to other primary care settings to improve hypertension control in underserved populations.
The trial demonstrates effectiveness and fidelity in 36 FQHCs, but scalability to other settings is an inference—implementation cost, fidelity, and maintenance were measured only within the study clinics, not in a scale-up context.
Evidence: Implemented in 36 FQHCs with fidelity score 2.8 vs 2.1 and cost $762/participant; no external scale-up or replication cohort is presented.
“This proven, multifaceted strategy is scalable to other primary care settings to improve hypertension control in underserved populations.”
DiscussionFind in source
partialReviewers 1, 2, 3
Our trial is the first to show that a multifaceted, team-based strategy effectively lowers blood pressure among low-income patients receiving care at FQHCs.
The effectiveness component is supported by the trial data, but the 'first' novelty claim is a field-level assertion not established by the paper's own evidence.
Evidence: The trial's net BP reduction of −6.4 mmHg supports effectiveness; the 'first to show' claim is asserted without a definitive systematic comparison of prior FQHC trials.
“Our trial is the first to show that a multifaceted, team-based strategy effectively lowers blood pressure among low-income patients receiving care at FQHCs.”
DiscussionFind in source
supportedReviewers 1, 2, 3
Compared to enhanced usual care, the multifaceted, team-based implementation strategy significantly lowered systolic blood pressure among low-income patients with hypertension.
The headline conclusion is directly backed by the primary outcome: net between-group difference of −6.4 mmHg (95% CI, −9.0 to −3.8; P<0.001), robust to adjustment and tipping-point analysis.
Evidence: Primary effectiveness outcome: net difference −6.4 mmHg (95% CI, −9.0 to −3.8; P<0.001); adjusted −5.6 (−8.1, −3.0); complete-case −7.1 (−9.7, −4.4); tipping-point analysis robust.
“Compared to enhanced usual care, the multifaceted, team-based implementation strategy significantly lowered systolic blood pressure among low-income patients with hypertension.”
AbstractFind in source
supportedReviewer 1
Intervention effectiveness was consistent across social determinants of health and cardiovascular risk factors.
Prespecified subgroup analyses by age, sex, race, education, income, insurance, CVD, CKD, diabetes, and baseline BP showed consistent BP reductions, backing the claim.
Evidence: Subgroup analyses reported as consistent across all listed strata (and supplementary figures).
“In predefined subgroup analyses, systolic blood pressure reduction appeared consistent across subgroups defined by age, sex, race, education, family income, health insurance status, history of cardiovascular disease, chronic kidney disease, diabetes, and baseline systolic blood pressure”
DiscussionFind in source
supportedReviewer 2
The multifaceted, team-based implementation strategy effectively reduced blood pressure and improved fidelity to hypertension treatment compared to enhanced usual care among populations experiencing health disparities.
Both primary outcomes (blood pressure reduction and fidelity score) are statistically significant, and the study population includes health disparity groups.
Evidence: Primary effectiveness and implementation outcomes in Results.
“This effectiveness-implementation trial demonstrated that a multifaceted, team-based strategy effectively reduced blood pressure and improved fidelity to hypertension treatment compared to enhanced usual care among populations experiencing health disparities.”
Discussion ¶1Find in source
supportedReviewer 3
The intervention improved fidelity to key hypertension-management components.
The fidelity summary score difference of 0.7 (95% CI, 0.6 to 0.8; P<0.001) directly supports improved implementation fidelity.
Evidence: Primary implementation outcome: fidelity summary score difference 0.7 (95% CI, 0.6 to 0.8; P<0.001).
“The mean fidelity score over the 18-month follow-up was 2.8 (95% CI, 2.7 to 2.9) in the intervention group and 2.1 (95% CI, 2.0 to 2.2) in the control group, with a between-group difference of 0.7 (95% CI, 0.6 to 0.8; P<0.001).”
AbstractFind in source

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

ADEQUATESurrogate endpoint
Primary efficacy endpoint is systolic blood pressure (SBP), a surrogate for cardiovascular outcomes. The manuscript explicitly cites SPRINT and other trials showing that intensive SBP lowering reduces cardiovascular disease events and mortality, providing a validated surrogate→clinical outcome link. Additionally, the intervention demonstrates target engagement through significant SBP reduction at the tested dose and cites meta-analyses of similar multifaceted strategies.
“The Systolic Blood Pressure Intervention Trial (SPRINT) demonstrated that intensive antihypertensive treatment targeting a systolic blood pressure <120 mm Hg significantly reduced cardiovascular disease events and all-cause mortality, compared to a target systolic blood pressure of <140 mm Hg.”
Find in source
ADEQUATEEffect size
Net between-group difference in SBP change was −6.4 mm Hg (95% CI, −9.0 to −3.8; P<0.001), which is clinically meaningful given SPRINT's demonstrated benefit from ~10 mmHg reductions and consistent with meta-analyses of multifaceted strategies (5–7 mmHg). The effect is statistically supported and anchored to clinical meaningfulness via cited trials.
“The mean systolic blood pressure decreased by −15.5 mmHg from baseline to 18 months in the intervention group and by −9.1 mmHg in the control group, with a net difference of −6.4 mmHg (95% CI, 9.0 to 3.8; P< 0.001).”
Find in source

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

3 findings · worst high

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data and code not sharedAssessed
Statistical reporting gaps (tests, assumptions, effect sizes)Assessed
Ethics/consent reporting incompleteAssessed

Eight Dimensions4 pass · 2 warn · 1 fail

Prior work on hypertension prevalence and control disparities is cited, and the limitations of previous research (e.g., lack of data in FQHCs, non-randomized designs) are acknowledged. The rationale links the need for evidence-based implementation strategies in underserved populations to the study objectives. All three sub-criteria are adequately addressed.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 90% conf

The premise is firmly grounded in prior literature (SPRINT, prior trials, meta-analyses) with a clear rationale and identification of the evidence gap in FQHC settings.

Evidence

“The Systolic Blood Pressure Intervention Trial (SPRINT) demonstrated that intensive antihypertensive treatment targeting a systolic blood pressure <120 mm Hg significantly reduced cardiovascular disease events and all-cause mortality”

Introduction ¶1Find in source

“data on implementing multifaceted blood pressure interventions in resource-constrained primary care settings, such as Federally Qualified Health Centers (FQHCs), which primarily serve low-income populations, are limited”

Introduction ¶2Find in source

“Prior hypertension control studies in FQHCs often used non-randomized designs and failed to demonstrate significant blood pressure reduction.”

DiscussionFind in source

PASSReviewer 2· 95% conf

The paper clearly establishes the scientific premise by citing prior work on hypertension disparities, the SPRINT trial, and previous implementation studies, and provides a logical rationale for the study.

Evidence

paraphrase[Introduction, paragraphs 1-3]

“However, data on implementing multifaceted blood pressure interventions in resource-constrained primary care settings, such as Federally Qualified Health Centers (FQHCs), which primarily serve low-income populations, are limited.”

Introduction ¶3Find in source

“There is a critical need to develop and test effective, scalable implementation strategies to translate evidence-based interventions into real-world primary care, particularly for underserved populations.”

Introduction ¶4Find in source

PASSReviewer 3· 90% conf

The scientific foundation is well established with extensive prior literature and a clear rationale linking uncontrolled hypertension in low-income populations to the need for scalable implementation strategies.

Evidence

IntroductionFind in source

Introduction ¶2Find in source

“Prior hypertension control studies in FQHCs often used non-randomized designs and failed to demonstrate significant blood pressure reduction.”

DiscussionFind in source

Clinics were randomized using SAS-generated random allocation with stratification. An a priori power analysis is provided (80% power to detect 5.0 mmHg difference). Intention-to-treat analysis with multiple imputation for missing data addresses outlier handling. The analysis plan is appropriate for a cluster-randomized trial.

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 90% conf

A well-designed cluster-randomized trial with explicit randomization, a priori power calculation, clear eligibility criteria, ITT analysis with multiple imputation, and stated open-label rationale.

Evidence

“FQHC clinics were randomized in a 1:1 ratio to either a multifaceted team-based implementation strategy or enhanced usual care based on a random allocation sequence generated using SAS software, with stratification by FQHC organization.”

MethodsFind in source

“This sample size provided 80% statistical power to detect a 5.0 mmHg difference in mean systolic blood pressure change over 18 months at a two-sided significance level of 0.05, with a follow-up rate of 85%.”

Statistical analysisFind in source

“An intention-to-treat analysis was conducted using multiple imputation for missing outcomes, assuming data were missing at random in the primary analyses”

Statistical analysisFind in source

PASSReviewer 2· 95% conf

The cluster-randomized design is rigorous, with adequate randomization, sample size justification, and clear inclusion/exclusion criteria. Blinding was not feasible but is described with rationale.

Evidence

MethodsFind in source

Statistical analysisFind in source

“Due to the nature of the cluster design and intervention program, study participants, healthcare providers, health coaches, and research staff who collected study data were unblinded.”

MethodsFind in source

PASSReviewer 3· 90% conf

The cluster-randomized design is rigorously specified: randomization method and unit, open-label rationale, a priori power calculation, eligibility criteria, and ITT analysis with multiple imputation are all reported.

Evidence

MethodsFind in source

“Due to the nature of the cluster design and intervention program, study participants, healthcare providers, health coaches, and research staff who collected study data were unblinded.”

MethodsFind in source

Statistical analysisFind in source

Sex is reported (56.7% women; Table 1: 58.7% vs 54.6% across groups), age and health status are reported (mean age 58.8 years; diabetes, CKD, prior CVD), and full demographics (race/ethnicity, education, income, insurance) are given in Table 1. Since both sexes were enrolled, a sex justification is not applicable. Species/strain and housing are not applicable for a human trial.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 85% conf

Sex, age, and extensive demographics are reported; health status is characterized via medical-history variables. Species/housing criteria are not applicable to a human trial.

Evidence

“Their mean age of patients was 58.8 years, 56.7% were women, 63.4% African American”

Table 1Find in source

“History of diabetes — no. (%) | 255 (39.7) | 248 (39.4)”

Table 1Find in source

“Non-Hispanic Black | 430 (67.1) | 376 (59.7)”

Table 1Find in source

PASSReviewer 2· 80% conf

Demographic variables (age, sex, race, income) are well-reported, but weight/BMI is not reported in baseline characteristics, which is a minor omission.

Evidence

paraphrase[Table 1]

“Women — no. (%) 377 (58.7)”

paraphrase[Table 1]

“Mean age is reported (58.8 years), but no weight or BMI is listed in the baseline characteristics.”

paraphrase[Table 1]

“Non-Hispanic Black 430 (67.1); Annual family income <$25,000 — no. (%) 468 (73.4)”

PASSReviewer 3· 90% conf

Participant demographic and clinical characteristics are thoroughly reported, including sex, age, race/ethnicity, comorbidities, and baseline blood pressure.

Evidence

“Their mean age of patients was 58.8 years, 56.7% were women, 63.4% African American, 75.9% unemployed, and 73.4% had a family income <$25,000 per year.”

AbstractFind in source

“History of diabetes — no. (%) | 255 (39.7) | 248 (39.4)”

Table 1Find in source

The study protocol was approved by the Tulane University Institutional Review Board. Informed consent was obtained from all participants. However, the paper does not mention adherence to a specific regulatory framework such as the Declaration of Helsinki or ICH-GCP, although IRB approval implies compliance with US regulations. This is a minor omission.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceNOT REPORTED

Per reviewer (3) — the votes behind the verdict

WARNReviewer 1· 75% conf

A named IRB approval and informed consent are documented, but no explicit statement of compliance with a recognized regulatory framework (e.g., Declaration of Helsinki) is given.

Evidence

“The study protocol (available online with the full text of this article) was designed by the steering committee and approved by the Tulane University Institutional Review Board.”

MethodsFind in source

“Informed consent was obtained from all participants during screening visits.”

MethodsFind in source

absence[Entire manuscript]

No named regulatory-compliance framework is stated.

WARNReviewer 2· 90% conf

IRB approval and informed consent are reported, but regulatory compliance (e.g., Declaration of Helsinki) is not explicitly stated, which is a minor reporting gap.

Evidence

paraphrase[Methods, Trial Design and Oversight]

“The study protocol was designed by the steering committee and approved by the Tulane University Institutional Review Board.”

“Informed consent was obtained from all participants during screening visits.”

MethodsFind in source

absence[Methods, Trial Design and Oversight; Discussion]

Regulatory compliance statement is absent.

WARNReviewer 3· 65% conf

A named IRB approval and informed consent are reported, but no explicit statement of compliance with a recognized regulatory framework (e.g., Declaration of Helsinki, ICH-GCP) is provided.

Evidence

“The study protocol (available online with the full text of this article) was designed by the steering committee and approved by the Tulane University Institutional Review Board.”

MethodsFind in source

“Informed consent was obtained from all participants during screening visits.”

MethodsFind in source

absence[Entire paper]

No named regulatory framework (e.g., Declaration of Helsinki) is mentioned.

The intervention is a team-based implementation strategy (protocol-based treatment, health coaching, home BP monitoring) rather than a drug, biologic, vaccine, or regulated investigational device. The automated BP device (HEM-907 XL, Omron Healthcare) and home monitors are standard measurement tools, not investigational products. Therefore antibodies, cell lines, mycoplasma, organisms, reagents, and bespoke software are all not applicable.

Sub-criteria

mycoplasma testingN/A

reagents identifiedN/A

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedN/A

Per reviewer (3) — the votes behind the verdict

N/AReviewer 1· 70% conf

This is a behavioral/implementation trial with no investigational drug, biologic, or device; the only instruments named are standard commercial BP devices, so no key biological or chemical resource criterion applies.

Evidence

“Three blood pressure measurements were taken at each visit using a standardized protocol with an automated device (HEM-907 XL, Omron Healthcare)”

MethodsFind in source

WARNReviewer 2· 80% conf

Statistical software is identified, but the investigational products (home BP monitors, antihypertensive medications) are not fully specified (e.g., brand, manufacturer).

Evidence

“Three blood pressure measurements were taken at each visit using a standardized protocol with an automated device (HEM-907 XL, Omron Healthcare)”

MethodsFind in source

“Each participant in the intervention clinics received a home blood pressure monitor”

MethodsFind in source

“Statistical analyses were performed using SAS V9.4 (SAS Institute, Cary, NC) and R V4.4.2 (R Foundation)”

Statistical analysisFind in source

N/AReviewer 3· 70% conf

This is a behavioral/procedural implementation trial with no investigational drug, biologic, or device under test; the Omron device is a standard measurement tool, so no key biological or chemical resource applies.

Evidence

“Three blood pressure measurements were taken at each visit using a standardized protocol with an automated device (HEM-907 XL, Omron Healthcare)”

MethodsFind in source

Tests are named (linear mixed-effects model, generalized linear mixed model). Assumptions are handled by the model design. Effect sizes with 95% CIs are reported for all outcomes. Software is identified. Data presentation is adequate for a clinical trial. The primary p-value is given as P<0.001, which is not exact, but secondary outcomes have exact p-values. This is a minor reporting deficiency.

Sub-criteria

tests namedADEQUATE

exact p valuesINADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 85% conf

Statistical methods are well-specified (linear/generalized mixed-effects models), software is identified, CIs are reported throughout, and the primary outcomes are reported with CIs and P<0.001; exact p-values are used for adverse events.

Evidence

“Statistical analyses were performed using SAS V9.4 (SAS Institute, Cary, NC) and R V4.4.2 (R Foundation)”

Statistical analysisFind in source

“with a net difference of −6.4 mmHg (95% CI, −9.0 to −3.8; P<0.001)”

Table 2Find in source

“with a between-group difference of 0.7 (95% CI, 0.6 to 0.8; P<0.001)”

Table 2Find in source

WARNReviewer 2· 85% conf

Statistical methods are appropriate and well-described, with effect sizes and CIs reported. However, the primary outcome p-value is reported as "P<0.001" instead of an exact value, which is imprecise.

Evidence

“with a net difference of −6.4 mmHg (95% CI, −9.0 to −3.8; P<0.001)”

ResultsFind in source

“Change in systolic BP from baseline to 18-month visit, mm Hg | −15.5 (−17.4, −13.6) | −9.1 (−11.0, −7.2) | −6.4 (−9.0, −3.8) | <0.001”

Table 2Find in source

“We tested the difference in mean systolic blood pressure from baseline to 18 months between the intervention and control groups using measurements taken at 0, 6, 12, and 18 months in a linear mixed-effects regression analysis.”

Statistical analysisFind in source

WARNReviewer 3· 60% conf

The statistical approach is rigorous and named (linear and generalized linear mixed-effects models), with effect estimates and 95% CIs; however, the co-primary outcome p-values are reported only as thresholds (P<0.001) rather than exact values.

Evidence

“with a net difference of −6.4 mmHg (95% CI, −9.0 to −3.8; P<0.001)”

AbstractFind in source

“Serious adverse event, % | 20.9 (15.5, 26.3) | 21.7 (18.1, 25.4) | −0.8 (−7.4, 5.7) | 0.80”

Table 2Find in source

“Statistical analyses were performed using SAS V9.4 (SAS Institute, Cary, NC) and R V4.4.2 (R Foundation)”

Statistical analysisFind in source

The paper does not include a data availability statement. Although the trial is registered at ClinicalTrials.gov, data access conditions are not described. No code repository is mentioned. This is a significant omission for transparency and reproducibility.

Sub-criteria

code sharingNOT REPORTED

accession numbersN/A

repository depositN/A

data availability statementNOT REPORTED

Per reviewer (3) — the votes behind the verdict

FAILReviewer 1· 60% conf

No data availability statement is present; the only applicable criterion for this patient-level trial is not reported.

Evidence

absence[Entire manuscript]

No data availability statement is present.

“The study protocol (available online with the full text of this article)”

MethodsFind in source

FAILReviewer 2· 95% conf

No data availability statement is present, and no code is shared. A clinical trial identifier is provided, but that does not constitute a data availability statement.

Evidence

absence[Entire paper]

No data availability statement found.

paraphrase[Abstract]

“ClinicalTrials.gov number NCT03483662”

absence[Entire paper]

No code sharing mentioned.

FAILReviewer 3· 70% conf

No data availability statement is present in the paper; for a clinical trial this is a required element and its absence is a substantive reporting gap.

Evidence

absence[Entire paper]

No data availability statement is provided.

“The study protocol (available online with the full text of this article) was designed by the steering committee and approved by the Tulane University Institutional Review Board.”

MethodsFind in source

Methods are detailed enough for replication. The trial is registered (NCT03483662). All outcomes are reported, including null results. Limitations are discussed openly. Conclusions are proportionate to the evidence. Funding is listed, but authors do not provide an explicit conflict of interest statement. A reporting guideline is not explicitly mentioned, but a CONSORT-like flow diagram is included.

Sub-criteria

funding coiINADEQUATE

trial registrationADEQUATE

reporting guidelineNOT REPORTED

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 80% conf

Methods are detailed, the trial is registered, all outcomes (including null ones) are reported, limitations are discussed, and conclusions are proportional; reporting-guideline and COI statements are missing.

Evidence

“ClinicalTrials.gov (http://ClinicalTrials.gov) number NCT03483662 (https://clinicaltrials.gov/ct2/show/NCT03483662)”

AbstractFind in source

“This study has several limitations related to its cluster design. The extended enrollment period prevented recruitment of all participants before randomization.”

DiscussionFind in source

“Research reported in this publication was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under Award Number R01HL133790.”

FundingFind in source

PASSReviewer 2· 90% conf

The manuscript is well-structured, reports all primary and secondary outcomes, discusses limitations, and conclusions are proportional. Funding is disclosed, but a formal conflict of interest statement is missing.

Evidence

paraphrase[Abstract]

“ClinicalTrials.gov number NCT03483662”

“This study has several limitations related to its cluster design. The extended enrollment period prevented recruitment of all participants before randomization.”

Discussion ¶6Find in source

“Research reported in this publication was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under Award Number R01HL133790.”

FundingFind in source

PASSReviewer 3· 80% conf

The manuscript is thorough and transparent: methods are detailed, the trial is registered, limitations and null safety outcomes are reported, and conclusions are proportional; however, no reporting checklist (CONSORT) is referenced and no COI statement appears.

Evidence

“ClinicalTrials.gov (http://ClinicalTrials.gov) number NCT03483662”

AbstractFind in source

“This study has several limitations related to its cluster design. The extended enrollment period prevented recruitment of all participants before randomization.”

DiscussionFind in source

“Research reported in this publication was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under Award Number R01HL133790.”

FundingFind in source

Registered (1 ID: ClinicalTrials.gov). No reporting guideline cited.

ClinicalTrials.gov

NCT03483662

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 29 references by DOI: 26 verified — 3 no DOI (shown, not verified).

NO DOI
New medication adherence scale versus pharmacy fill rates in seniors with hypertension
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Applied Longitudinal Analysis
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
The Surgeon General’s Call to Action to Control Hypertension
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).

1 data/code link checked; 1 live.

datahttps://clinicaltrials.gov/ct2/show/NCT03483662LIVEHTTP 200
Resolves, but the content could not be matched to the paper.

Copyediting

1 finding · worst low

Wording, consistency and formatting errors that need correcting before submission.

Wording or formatting errors that need correctingAssessed

9 copyedit issues flagged (2 major): mostly typo, consistency, punctuation.

MAJORconsistencyResults, Effectiveness Outcomes
“net difference of −6.4 mmHg (95% CI, 9.0 to 3.8; P< 0.001)”
→ net difference of −6.4 mmHg (95% CI, −9.0 to −3.8; P<0.001)
Minus signs missing from the CI bounds, contradicting Table 2 which shows (−9.0, −3.8).
MAJORconsistencyResults, Effectiveness Outcomes
“net difference of −3.4 mmHg (95% CI, 5.1 to 1.8)”
→ net difference of −3.4 mmHg (95% CI, −5.1 to −1.8)
Minus signs missing from the CI bounds for the diastolic BP difference.
MINORtypoAuthor affiliation list
“RKM Primary Care (DG), Cliton, LA”
→ RKM Primary Care (DG), Clinton, LA
Likely misspelling of 'Clinton'.
MINORpunctuationAbstract; Results
“P< 0.001”
→ P<0.001
Inconsistent spacing around '<' in p-value formatting.
MINORtypoResults, Effectiveness Outcomes
“net difference of −6.4 mmHg (95% CI, 9.0 to 3.8; P<0.001)”
→ Change to: net difference of −6.4 mmHg (95% CI, −9.0 to −3.8; P<0.001)
Missing minus signs on the confidence interval bounds.
MINORtypoResults, Effectiveness Outcomes
“net difference of −3.4 mmHg (95% CI, 5.1 to 1.8)”
→ Change to: net difference of −3.4 mmHg (95% CI, −5.1 to −1.8)
Missing minus signs on the confidence interval bounds.
MINORconsistencyResults, Effectiveness Outcomes
“with a net difference of −6.4 mmHg (95% CI, 9.0 to 3.8; P< 0.001)”
→ with a net difference of −6.4 mmHg (95% CI, −9.0 to −3.8; P<0.001)
Minus signs are missing from the CI bounds; the abstract and Table 2 show −9.0 to −3.8.
MINORtypoAuthor affiliations
“RKM Primary Care (DG), Cliton, LA”
→ RKM Primary Care (DG), Clinton, LA
Misspelling of the Louisiana town name.
MINORpunctuationResults, Effectiveness Outcomes
“P< 0.001”
→ P<0.001
Stray space after the less-than sign.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published paper is robust in its design and primary findings, but the absence of a data availability statement and the overstated scalability claim warrant caution. Informed readers should weigh the missing data access and the limited evidence for scalability. The authors should consider publishing a correction to add a data availability statement and correct the CI minus signs.

1.
HIGHdata code
Add a data availability statement (e.g., 'De-identified participant data will be shared via a named managed-access platform upon request with conditions') in a dedicated Data Availability section; this is a significant gap for a clinical trial and warrants a correction.
Without a data availability statement, the data are not accessible, undermining reproducibility and transparency.
2.
HIGHcopyedit
Correct the missing minus signs in the CI bounds for the primary and diastolic BP outcomes in the Results text (e.g., change '95% CI, 9.0 to 3.8' to '−9.0 to −3.8').
The current text contradicts Table 2 and is a clear transcription error that could mislead readers.
3.
HIGHrigor
Temper the claim that the strategy is 'scalable to other primary care settings' (conclusion) to reflect that the trial did not test scale-up; add a discussion of implementation costs, fidelity maintenance, and generalizability constraints.
The claim audit found this conclusion overstated; the evidence supports effectiveness in 36 FQHCs, but scalability is an inference not directly tested.
4.
HIGHstatistics
Report exact p-values for the co-primary outcomes (e.g., P<0.0001 or the precise value) in the Results and Table 2, or state the reporting convention explicitly.
Threshold reporting (P<0.001) is imprecise and does not meet current best practices for exact p-value reporting.
5.
HIGHethics
Add an explicit statement of regulatory compliance (e.g., 'conducted in accordance with the Declaration of Helsinki') in the Methods, Trial Design and Oversight section.
A named regulatory framework is a standard reporting requirement and is currently missing.
6.
HIGHreporting
Add a conflict-of-interest disclosure statement for all authors in a dedicated section, even if none exist.
A formal COI statement is required by most journals and is currently absent.
7.
MEDIUMreporting
Reference the CONSORT extension for cluster randomized trials and state that the checklist was followed in the Methods section.
Adherence to a reporting guideline is a transparency measure and is currently not mentioned.
8.
MEDIUMother
Add the home blood pressure monitor brand/model to the Methods section for replication purposes.
One reviewer noted that the home monitor brand is unspecified, which could affect reproducibility of the intervention.
9.
LOWcopyedit
Correct the misspelling of 'Clinton, LA' in the author affiliation list.
Minor typographical error that should be corrected in a corrigendum.
10.
LOWcopyedit
Fix the inconsistent spacing in p-value formatting (e.g., 'P< 0.001' to 'P<0.001') throughout the manuscript.
Consistency in formatting improves readability.
11.
LOWother
Report the mean body-mass index or weight of participants in the baseline characteristics table.
Weight/BMI is a standard baseline variable and its absence is a minor omission.

Full text (35,415 chars)Analyzed: Aug 10, 2026

RigorReviewer 1

RigorReviewer 2

RigorReviewer 3

RigorPre-Submission Reviewer

CopyeditAgent Scribe

CitationsCitation Integrity

StatisticsStatistics Consistency

ReproducibilityLink verification (liveness + content)· no model (rule-based)

PreregistrationDeterministic check· no model (rule-based)

The star rating is the report’s one-glance summary. Every paper starts at 5★ and loses stars for the concrete problems the review finds — so a rating is never a vague average, it’s a running total you can read line by line under “How this rating was calculated.”

How stars are deducted

Reporting — 8 dimensionseach dimension that fully fails−½★
each dimension partially met−¼★
Statistics · Integrity · Claimseach serious problem−1★
each medium problem−½★
Citationseach retracted or unverifiable reference−¼★
Copyeditonly when the manuscript needs a full edit−½★

The rating never drops below 1★, and a demonstrable critical failure (an impossible statistic, a proven ethics violation) caps it at 1★ on its own — so the stars can never look healthy when the verdict is CRITICAL.

The rating draws on a panel of agents. Three independent Kaimen Rigor reviewers grade the eight dimensions below across several independent passes (the shown verdict is their majority vote — steadier than any single run), isolate the paper’s major claims and check its own evidence backs them, and flag integrity concerns. Alongside them, a citation agent resolves every reference against Crossref, OpenAlex, and Retraction Watch; a statistics agent recomputes reported tests; and rule-based checks verify that declared data/code links actually resolve. Full text is required — an abstract-only submission is not analyzed.

The eight reporting dimensions

Scientific PremisePrior work, rationale, and how it addresses gaps.

Study Design & RigorRandomization, blinding, power, controls, replication.

Biological VariablesSex, age, species/strain, housing, demographics.

Ethical ApprovalsIRB/IACUC approval, informed consent, regulatory compliance.

Key ResourcesAntibodies, cell lines, organisms, software — identified with persistent IDs.

Statistical ReportingNamed tests, exact p-values, effect sizes, plausible summary stats.

Data & Code AvailabilityAvailability statements, repositories, accession numbers, shared code.

Reporting TransparencyMethods, registration, guidelines, outcomes, limitations, funding/COI.

Graded against NIH, MDAR, ARRIVE 2.0, CONSORT, EQUATOR, and RRID guidelines. A dimension that doesn’t apply to the study type is skipped, never penalized.

This Kaimen Rigor review is model-assisted and is not a substitute for formal expert review. It complements human evaluation by surfacing potential methodological concerns — verify each finding against the source.

Multifaceted Strategies for Hypertension Control in Low-Income Patients.

DOI

10.1056/NEJMoa2504068

Record issued

2026-08-10

Engine

7.29.0

Exported

2026-09-21